Why take this course?
Statistical Process Control (SPC) provides a structured way to monitor process behavior, distinguish meaningful change from routine variation, and support production and quality decisions across CGMP manufacturing. FDA expectations increasingly emphasize appropriate statistical techniques for establishing, controlling, and verifying process capability, product characteristics, sampling plans, validation evidence, and recurring quality trends. Used effectively, SPC can strengthen production control while reducing avoidable rework and scrap.
This webinar examines how SPC, Six Sigma concepts, control charts, capability measures, sampling justification, and trend analysis can be applied to regulated manufacturing and laboratory operations. Participants will consider common cause versus special cause variation, equipment monitoring, verification and validation studies, and the use of nonconformance, complaint, and CAPA data as early indicators of process change. The focus is on using process data to support consistent quality, stability, and manufacturing decisions under CGMP expectations.
Key Areas Covered
John E. Lincoln
John E. Lincoln has over 40 years of experience in FDA-regulated industries, including quality assurance, regulatory affairs, process and product validation, QMS remediation, and manufacturing engineering. His background across regulated manufacturing and validation supports the practical application of SPC, process capability, statistical controls, and production data to quality and manufacturing decisions.
Commonly Asked Questions About This Subject
When should a statistically significant process change trigger investigation if all product results remain within specification?
A statistically meaningful shift can warrant investigation before any specification failure occurs. Waiting for an OOS result can defeat much of the value of process monitoring because the process may have been changing for several batches before product acceptance criteria were threatened.
The decision should consider the magnitude and persistence of the shift, process capability, relationship of the affected parameter to product quality, historical behavior, and whether an assignable cause can reasonably be identified. A single unusual point and a sustained directional movement should not automatically receive the same response.
Inspection friction develops when control charts or trend reports clearly show changing behavior but there is no documented assessment because every batch passed release testing. That suggests the statistical system was being maintained without influencing manufacturing decisions.
A strong record shows that the signal was recognized, technically assessed, and either escalated or closed with a documented rationale based on process knowledge and product risk.
How should teams respond when a process is statistically stable but its capability is too close to the specification limits?
Stable performance does not provide much comfort when normal process variation leaves insufficient room between routine operation and the specification limits. A process can behave predictably while still carrying an unacceptable probability of producing nonconforming output.
This situation deserves management attention before failures begin appearing. The practical question is whether the observed capability provides enough margin for normal sources of variation such as raw material differences, equipment wear, environmental conditions, operators, or measurement uncertainty.
What becomes difficult to defend is repeated acceptance of marginal capability simply because recent batches passed. Historical conformance can support the assessment, but it does not explain why future performance should remain acceptable when the available operating margin is already narrow.
A sound decision documents the capability assessment, product risk, known sources of variation, and any monitoring or improvement actions considered necessary. That demonstrates active process control rather than dependence on finished-product testing to detect deterioration.
What makes a statistical sampling plan difficult to defend during an FDA inspection?
A sampling plan becomes vulnerable when the sample size was inherited, copied from a procedure, or selected for convenience without a documented connection to the decision being made. An inspector can quickly move from asking what the sample size is to asking why that number provides sufficient evidence.
The justification should reflect the purpose of sampling, expected variability, severity of an incorrect decision, process knowledge, and the confidence required from the resulting data. Sampling twenty units because "that is our standard practice" carries considerably less weight than a rationale tied to the specific process and risk.
Problems also arise when the same sampling approach is used for routine acceptance, validation, investigations, and process changes even though those activities answer different questions.
The strongest documentation shows that the organization understood what conclusion the sample was expected to support and selected an approach capable of supporting that conclusion. Statistical calculations matter, but their assumptions and intended use need to make operational sense.
How should quality teams handle repeated minor trends that never individually cross established statistical or procedural limits?
Repeated minor signals should be evaluated collectively when they begin forming a pattern. One of the easiest process problems to miss is a gradual deterioration composed entirely of observations that remain individually acceptable.
This occurs when each complaint category, minor nonconformance, adjustment, yield change, or process fluctuation is reviewed against its own trigger and closed because no threshold was exceeded. Months later, the combined data may show that process behavior had been changing well before a significant event occurred.
Inspection questions become uncomfortable when the information was available but fragmented across reports or quality systems and nobody evaluated the cumulative signal. Established alert limits should therefore support judgment rather than prevent it.
Periodic cross-functional review can determine whether apparently unrelated indicators share a product, equipment, material, process step, supplier, or time-based relationship. Detecting that relationship early provides stronger evidence of process understanding and often prevents substantially more expensive investigations and corrective actions later.
Your TalkFDA Webinar Experience
1. Confirmation
3. Join the Live Training
4. Watch Again Anytime
Testimonials
Ready to Strengthen Your Team? Let’s Build Your Training Plan.
Your team deserves the clarity.
Your organization deserves the confidence.


